请输入您要查询的百科知识：

　

词条 Immune checkpoint
释义

  1. Stimulatory checkpoint molecules

  2. Inhibitory checkpoint molecules

  3. Immune checkpoint inhibitors

  4. References

{{primary|date=November 2018}}

Immune checkpoints are regulators of the immune system. These pathways are crucial for self-tolerance, which prevents the immune system from attacking cells indiscriminately.

Inhibitory checkpoint molecules are targets for cancer immunotherapy due to their potential for use in multiple types of cancers. Currently approved checkpoint inhibitors block CTLA4 and PD-1 and PD-L1. For the related basic science discoveries, James P. Allison and Tasuku Honjo won the Tang Prize in Biopharmaceutical Science and the Nobel Prize in Physiology or Medicine in 2018.[1][2]

Stimulatory checkpoint molecules

Four stimulatory checkpoint molecules are members of the tumor necrosis factor (TNF) receptor superfamily—CD27, CD40, OX40, GITR and CD137. Another two stimulatory checkpoint molecules belongs to the B7-CD28 superfamily—CD28 itself and ICOS.

  • CD27: This molecule supports antigen-specific expansion of naïve T cells and is vital for the generation of T cell memory.[3] CD27 is also a memory marker of B cells.[4] CD27's activity is governed by the transient availability of its ligand, CD70, on lymphocytes and dendritic cells.[5] CD27 costimulation is known to suppresses Th17 effector cell function.[6] The American biotech company Celldex Therapeutics is working on CDX-1127, an agonistic anti-CD27 monoclonal antibody[7] which in animal models has been shown to be effective in the context of T cell receptor stimulation.[8]
  • CD28: This molecule is constitutively expressed on almost all human CD4+ T cells and on around half of all CD8 T cells. Binding with its two ligands are CD80 and CD86, expressed on dendritic cells, prompts T cell expansion. CD28 was the target of the TGN1412 'superagonist' which caused severe inflammatory reactions in the first-in-man study in London in March 2006.[9]
  • CD40: This molecule, found on a variety of immune system cells including antigen presenting cells has CD40L, otherwise known as CD154 and transiently expressed on the surface of activated CD4+ T cells, as its ligand. CD40 signaling is known to ‘license’ dendritic cells to mature and thereby trigger T-cell activation and differentiation.[10] A now-defunct Seattle-based biotechnology company called VLST in-licensed an anti-CD40 agonist monoclonal antibody from Pfizer in 2012. The Swiss pharmaceutical company Roche acquired this project when VLST was shut down in 2013.[11]
  • CD122: This molecule, which is the Interleukin-2 receptor beta sub-unit, is known to increase proliferation of CD8+ effector T cells.[12] The American biotechnology company Nektar Therapeutics is working on NKTR-214, a CD122-biased immune-stimulatory cytokine[13] Phase I results announced in Nov 2016.[14]
  • CD137: When this molecule, also called 4-1BB, is bound by CD137 ligand, the result is T-cell proliferation. CD137-mediated signaling is also known to protect T cells, and in particular, CD8+ T cells from activation-induced cell death.[15] The German biotech company Pieris Pharmaceuticals has developed an engineered lipocalin that is bi-specific for CD137 and HER2.[16]
  • OX40: This molecule, also called CD134, has OX40L, or CD252, as its ligand. Like CD27, OX40 promotes the expansion of effector and memory T cells, however it is also noted for its ability to suppress the differentiation and activity of T-regulatory cells, and also for its regulation of cytokine production.[17] OX40's value as a drug target primarily lies in the fact that, being transiently expressed after T-cell receptor engagement, it is only upregulated on the most recently antigen-activated T cells within inflammatory lesions.[18] Anti-OX40 monoclonal antibodies have been shown to have clinical utility in advanced cancer.[19] The pharma company AstraZeneca has three drugs in development targeting OX40: MEDI0562 is a humanised OX40 agonist; MEDI6469, murine OX4 agonist; and MEDI6383, an OX40 agonist[20]
  • GITR: short for Glucocorticoid-Induced TNFR family Related gene, prompts T cell expansion, including Treg expansion.[21] The ligand for GITR is mainly expressed on antigen presenting cells.[22] Antibodies to GITR have been shown to promote an anti-tumor response through loss of Treg lineage stability.[23] The biotech company TG Therapeutics is working on anti-GITR antibodies[24]
  • ICOS: This molecule, short for Inducible T-cell costimulator, and also called CD278, is expressed on activated T cells. Its ligand is ICOSL, expressed mainly on B cells and dendritic cells. The molecule seems to be important in T cell effector function.[25] The American biotechnology company Jounce Therapeutics is developing an ICOS agonist.

Inhibitory checkpoint molecules

  • A2AR: The Adenosine A2A receptor is regarded as an important checkpoint in cancer therapy because adenosine in the immune microenvironment, leading to the activation of the A2a receptor, is negative immune feedback loop and the tumor microenvironment has relatively high concentrations of adenosine.[26]
  • B7-H3: also called CD276, was originally understood to be a co-stimulatory molecule[27] but is now regarded as co-inhibitory.[28] The American biotechnology company MacroGenics is working on MGA271 is an Fc-optimized monoclonal antibody that targets B7-H3.[29] B7-H3’s receptors have not yet been identified.[30]
  • B7-H4: also called VTCN1, is expressed by tumor cells and tumor-associated macrophages and plays a role in tumour escape.[31]
  • BTLA: This molecule, short for B and T Lymphocyte Attenuator and also called CD272, has HVEM (Herpesvirus Entry Mediator) as its ligand. Surface expression of BTLA is gradually downregulated during differentiation of human CD8+ T cells from the naive to effector cell phenotype, however tumor-specific human CD8+ T cells express high levels of BTLA.[32]
  • CTLA-4: short for Cytotoxic T-Lymphocyte-Associated protein 4 and also called CD152, is the target of Bristol-Myers Squibb's melanoma drug Yervoy, which gained FDA approval in March 2011. Expression of CTLA-4 on Treg cells serves to control T cell proliferation.[33][34]
  • IDO: short for Indoleamine 2,3-dioxygenase, is a tryptophan catabolic enzyme with immune-inhibitory properties. Another important molecule is TDO, tryptophan 2,3-dioxygenase. IDO is known to suppress T and NK cells, generate and activate Tregs and myeloid-derived suppressor cells, and promote tumour angiogenesis.[35][34]
  • KIR: short for Killer-cell Immunoglobulin-like Receptor, is a receptor for MHC Class I molecules on Natural Killer cells. Bristol-Myers Squibb is working on Lirilumab, a monoclonal antibody to KIR.
  • LAG3: short for Lymphocyte Activation Gene-3, works to suppress an immune response by action to Tregs[36] as well as direct effects on CD8+ T cells.[37][34] Bristol-Myers Squibb is in Phase I with an anti-LAG3 monoclonal antibody called BMS-986016.[38]
  • NOX2: short for nicotinamide adenine dinucleotide phosphate NADPH oxidase isoform 2, is an enzyme of myeloid cells that generates immunosuppressive reactive oxygen species. Genetic and pharmacological inhibition of NOX2 in myeloid cells improves anti-tumor functions of adjacent NK cells and T cells and also triggers autoimmunity in humans and experimental animals. NOX2 is the target of Ceplene that has gained approval for use in acute myeloid leukemia within the EU. [39][34]
  • PD-1: short for Programmed Death 1 (PD-1) receptor, has two ligands, PD-L1 and PD-L2. This checkpoint is the target of Merck & Co.'s melanoma drug Keytruda, which gained FDA approval in September 2014. The checkpoint is also the target of EMD Serono (Merck KGaA)'s drug Bavencio, which gained FDA approval in 2017. An advantage of targeting PD-1 is that it can restore immune function in the tumor microenvironment.[40][34]
  • TIM-3: short for T-cell Immunoglobulin domain and Mucin domain 3, expresses on activated human CD4+ T cells and regulates Th1 and Th17 cytokines.[41] TIM-3 acts as a negative regulator of Th1/Tc1 function by triggering cell death upon interaction with its ligand, galectin-9.[42][34]
  • VISTA (protein): Short for V-domain Ig suppressor of T cell activation, VISTA is primarily expressed on hematopoietic cells[43] so that consistent expression of VISTA on leukocytes within tumors may allow VISTA blockade to be effective across a broad range of solid tumors.[44][34]
  • SIGLEC7 (Sialic acid-binding immunoglobulin-type lectin 7, also designated as CD328) and SIGLEC9 (Sialic acid-binding immunoglobulin-type lectin 9, also designated as CD329) are proteins found on the surface of various immune cells, including natural killer cells and macrophages (SIGLEC7) and neutrophils, macrophages, dendritic cells and activated T-cells (SIGLEC9).[45] SIGLECs 7 and 9 suppress the immune function of these cells by binding to terminal sialic acid on glycans that cover the surface of cells.[46][47]

Immune checkpoint inhibitors

Drugs or drug candidates that inhibit/block the inhibitory checkpoint molecules are sometimes known as checkpoint inhibitors; this idea is often referred to as immune checkpoint blockade, or simply checkpoint blockade.[48][34] Checkpoint inhibitor drugs have seen growth in pharmaceutical research in cancer by companies including Bristol-Myers Squibb, Merck, Merck KGaA, Roche and AstraZeneca.[49] A new area of checkpoint inhibitor drugs is being pursued by Palleon Pharmaceuticals, who are working on inhibiting SIGLEC 7 and SIGLEC 9 as a new class of receptors for antibody therapeutics.

References

1. ^{{Cite web |url=https://web.archive.org/web/20171020051653/http://www.tang-prize.org/en/owner.php?cat=11&y=2 |title=2014 Tang Prize in Biopharmaceutical Science |access-date=2016-06-18 |archive-url= |archive-date=2016-06-20 |dead-url=no |df= }}
2. ^{{cite web | last=Devlin | first=Hannah | title=James P Allison and Tasuku Honjo win Nobel prize for medicine | website=the Guardian | date=2018-10-01 | url=https://www.theguardian.com/science/2018/oct/01/james-p-allison-and-tasuku-honjo-win-nobel-prize-for-medicine | access-date=2018-10-01}}
3. ^{{cite journal |author1=Hendriks J |author2=Gravestein LA |author3=Tesselaar K |author4=van Lier RA |author5=Schumacher TN |author6=Borst J. |title=CD27 is required for generation and long-term maintenance of T cell immunity |journal=Nat Immunol |volume=1 |issue=5 |pages=433–40 |date=November 1, 2000 |doi= 10.1038/80877 |pmid=11062504}}
4. ^{{cite journal |author=Agematsu K |title=Memory B cells and CD27 |journal=Histology and Histopathology |volume=15 |issue=2 |pages=573–6 |date=April 1, 2000 |doi= |pmid=10809378}}
5. ^{{cite journal |vauthors=Borst J, Hendriks J, Xiao Y |title=CD27 and CD70 in T cell and B cell activation |journal=Curr Opin Immunol |volume=17 |issue=3 |pages=275–81 |date=June 1, 2005 |doi= 10.1016/j.coi.2005.04.004 |pmid=15886117}}
6. ^{{cite journal |vauthors=Coquet JM, Middendorp S, van der Horst G, Kind J, Veraar EA, Xiao Y, Jacobs H, Borst J |title=The CD27 and CD70 costimulatory pathway inhibits effector function of T helper 17 cells and attenuates associated autoimmunity |journal=Immunity |volume=38 |issue=1 |pages=53–65 |date=January 24, 2013 |doi= 10.1016/j.immuni.2012.09.009 |pmid=23159439}}
7. ^{{cite web|title=CDX-1127 – Monoclonal Antibody Targeting CD27|url=http://www.celldex.com/pipeline/cdx-1127.php|publisher=Celldex Therapeutics}}
8. ^{{cite journal |vauthors=He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A, Pilsmaker CD, Round SM, Tutt A, Glennie MJ, Marsh H, Keler T |title=Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice |journal=J Immunol |volume=191 |issue=8 |pages=4174–83 |date=October 15, 2013 |doi= 10.4049/jimmunol.1300409 |pmid=24026078}}
9. ^{{cite journal |vauthors=Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M, Moore M, Burns C, Thorpe R, Stebbings R |title=Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells |journal=Br J Pharmacol |volume=161 |issue=3 |pages=512–526 |date=October 1, 2010 |doi= 10.1111/j.1476-5381.2010.00922.x |pmid=20880392 |pmc=2990151}}
10. ^{{cite journal |vauthors=O'Sullivan B, Thomas R |title=CD40 and dendritic cell function |journal=Crit Rev Immunol |volume=23 |issue=1 |pages=83–107 |date=January 1, 2003 |doi= 10.1615/critrevimmunol.v23.i12.50 |pmid=12906261}}
11. ^{{cite news|last1=Zimm|first1=Angela|title=Cancer ‘Miracle’ Patients Studied Anew for Disease Clues|url=https://www.bloomberg.com/news/articles/2014-04-11/cancer-miracle-patients-studied-anew-for-disease-clues|accessdate=25 June 2015|work=Bloomberg|date=April 12, 2014}}
12. ^{{cite journal |vauthors=Boyman O, Sprent J |title=The role of interleukin-2 during homeostasis and activation of the immune system |journal=Nat Rev Immunol |volume=12 |issue=3 |pages=180–190 |date=February 17, 2012 |doi= 10.1038/nri3156 |pmid=22343569}}
13. ^{{cite news|title=Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine|url=http://ir.nektar.com/releasedetail.cfm?ReleaseID=915967|accessdate=25 June 2015|work=Nektar Therapeutics|date=June 2, 2015}}
14. ^[https://immuno-oncologynews.com/2016/11/17/nektar-therapeutics-presents-clinical-data-from-ongoing-escalation-study-of-nktr-214-in-solid-tumors/ Immunotherapy, NKTR-214, Shows Activity Against Solid Tumors in Clinical Trial]
15. ^{{cite journal |vauthors=Mittler RS, Foell J, McCausland M, Strahotin S, Niu L, Bapat A, Hewes LB |title=Anti-CD137 antibodies in the treatment of autoimmune disease and cancer |journal=Immunol Res |volume=29 |issue=1 |pages=197–208 |date=June 1, 2004 |doi= 10.1385/ir:29:1-3:197 |pmid=15181282}}
16. ^{{cite news|title=Pieris Pharmaceuticals to present data on novel anti-CD137 and HER2 bispecific immuno-oncology program at UBS Global Healthcare Conference|url=http://www.pieris.com/news-and-events/press-releases/detail/500/pieris-pharmaceuticals-to-present-data-on-novel-anti-cd137|accessdate=5 June 2015|publisher=Pieris Pharmaceuticals|date=19 May 2015}}
17. ^{{cite journal |vauthors=Croft M, So T, Duan W, Soroosh P |title=The significance of OX40 and OX40L to T-cell biology and immune disease |journal=Immunol Rev |volume=229 |issue=1 |pages=173–91 |date=May 1, 2009 |doi= 10.1111/j.1600-065x.2009.00766.x |pmid=19426222 |pmc=2729757}}
18. ^{{cite journal |vauthors=Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD |title=Science gone translational: the OX40 agonist story. |journal=Immunol Rev |volume=244 |issue=1 |pages=218–31 |date=November 1, 2011 |doi= 10.1111/j.1600-065x.2011.01069.x |pmid=22017441 |pmc=3622727}}
19. ^{{cite journal |author1=Curti BD |author2=Kovacsovics-Bankowski M |author3=Morris N |author4=Walker E |author5=Chisholm L |author6=Floyd K |author7=Walker J |author8=Gonzalez I |author9=Meeuwsen T |author10=Fox BA |author11=Moudgil T |author12=Miller W |author13=Haley D |author14=Coffey T |author15=Fisher B |author16=Delanty-Miller L |author17=Rymarchyk N |author18=Kelly T |author19=Crocenzi T |author20=Bernstein E |author21=Sanborn R |author22=Urba WJ |author23=Weinberg AD. |title=OX40 is a potent immune-stimulating target in late-stage cancer patients |journal=Cancer Res |volume=73 |issue=24 |pages=7189–98 |date=December 15, 2013 |doi= 10.1158/0008-5472.can-12-4174 |pmid=24177180 |pmc=3922072}}
20. ^{{cite news|title=Q1 2015 Result|url=http://www.astrazeneca.com/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-Disposition&blobheadername2=MDT-Type&blobheadervalue1=inline%3B+filename%3DDownload-press-release-amp-pipeline-update.pdf&blobheadervalue2=abinary%3B+charset%3DUTF-8&blobkey=id&blobtable=MungoBlobs&blobwhere=1285691535910&ssbinary=true|accessdate=5 June 2015|publisher=AstraZeneca|date=24 April 2015}}
21. ^{{cite journal |vauthors=Ronchetti S, Zollo O, Bruscoli S, Agostini M, Bianchini R, Nocentini G, Ayroldi E, Riccardi C |title=GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations. |journal=Eur J Immunol |volume=34 |issue=3 |pages=613–22 |date=March 1, 2004 |doi= 10.1002/eji.200324804 |pmid=14991590}}
22. ^{{cite journal |vauthors=Nocentini G, Ronchetti S, Cuzzocrea S, Riccardi C |title=GITR/GITRL: more than an effector T cell co-stimulatory system |journal=Eur J Immunol |volume=37 |issue=5 |pages=1165–9 |date=May 1, 2007 |doi= 10.1002/eji.200636933 |pmid=17407102}}
23. ^{{cite journal |vauthors=Schaer DA, Budhu S, Liu C, Bryson C, Malandro N, Cohen A, Zhong H, Yang X, Houghton AN, Merghoub T, Wolchok JD |title=GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability |journal=Cancer Immunol Res |volume=1 |issue=5 |pages=320–31 |date=November 1, 2013 |doi= 10.1158/2326-6066.cir-13-0086 |pmid=24416730 |pmc=3885345}}
24. ^{{cite news|title=TG Therapeutics Enters Into a Global Collaboration With Checkpoint Therapeutics to Develop and Commercialize Novel Immuno-Oncology Targeted Antibodies|url=http://ir.tgtherapeutics.com/releasedetail.cfm?ReleaseID=899887|accessdate=5 June 2015|publisher=TG Therapeutics|date=4 March 2015}}
25. ^{{cite journal |vauthors=Burmeister Y, Lischke T, Dahler AC, Mages HW, Lam KP, Coyle AJ, Kroczek RA, Hutloff A |title=ICOS controls the pool size of effector-memory and regulatory T cells |journal=J Immunol |volume=180 |issue=2 |pages=774–782 |date=January 15, 2008 |doi= 10.4049/jimmunol.180.2.774 |pmid=18178815}}
26. ^{{cite journal |vauthors=Leone RD, Lo YC, Powell JD |title=A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy |journal=Comput Struct Biotechnol J |volume=13 |issue= |pages=265–72 |date=April 8, 2015 |doi= 10.1016/j.csbj.2015.03.008 |pmid=25941561 |pmc=4415113}}
27. ^{{cite journal |vauthors=Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, Dong H, Sica GL, Zhu G, Tamada K, Chen L |title=B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production |journal=Nat Immunol |volume=2 |issue=3 |pages=269–74 |date=March 1, 2001 |doi= 10.1038/85339 |pmid=11224528}}
28. ^{{cite journal |vauthors=Leitner J, Klauser C, Pickl WF, Stöckl J, Majdic O, Bardet AF, Kreil DP, Dong C, Yamazaki T, Zlabinger G, Pfistershammer K, Steinberger P |title=B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction |journal=Eur J Immunol |volume=39 |issue=7 |pages=1754–64 |date=July 1, 2009 |doi= 10.1002/eji.200839028 |pmid=19544488 |pmc=2978551}}
29. ^{{cite news|title=MacroGenics Provides Update on Corporate Progress and First Quarter 2015 Financial Results|url=http://ir.macrogenics.com/releasedetail.cfm?ReleaseID=911389|accessdate=5 June 2015|publisher=MacroGenics|date=6 May 2015}}
30. ^{{cite journal |vauthors=Mao Y, Li W, Chen K, Xie Y, Liu Q, Yao M, Duan W, Zhou X, Liang R, Tao M |title=B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer |journal=Oncotarget |volume=6 |issue=5 |pages=3452–61 |date=February 20, 2015 |doi= 10.18632/oncotarget.3097 |pmid=25609202 |pmc=4413666}}
31. ^{{cite journal |vauthors=Dangaj D, Lanitis E, Zhao A, Joshi S, Cheng Y, Sandaltzopoulos R, Ra HJ, Danet-Desnoyers G, ((Powell DJ Jr)), Scholler N |title=Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses |journal=Cancer Res |volume=73 |issue=15 |pages=4820–9 |date=August 1, 2013 |doi= 10.1158/0008-5472.can-12-3457 |pmid=23722540 |pmc=3732560}}
32. ^{{cite journal |vauthors=Derré L, Rivals JP, Jandus C, Pastor S, Rimoldi D, Romero P, Michielin O, Olive D, Speiser DE |title=BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination |journal=J Clin Invest |volume=120 |issue=1 |pages=157–67 |date=January 1, 2010 |doi= 10.1172/jci40070 |pmid=20038811 |pmc=2799219}} {{open access}}
33. ^{{cite journal |vauthors=Kolar P, Knieke K, Hegel JK, Quandt D, Burmester GR, Hoff H, Brunner-Weinzierl MC |title=CTLA-4 (CD152) controls homeostasis and suppressive capacity of regulatory T cells in mice |journal=Arthritis Rheum |volume=60 |issue=1 |pages=123–32 |date=January 1, 2009 |doi= 10.1002/art.24181 |pmid=19116935}}
34. ^1 2 3 4 5 6 7 {{Cite journal|last=Syn|first=Nicholas L|last2=Teng|first2=Michele W L|last3=Mok|first3=Tony S K|last4=Soo|first4=Ross A|title=De-novo and acquired resistance to immune checkpoint targeting|url=http://linkinghub.elsevier.com/retrieve/pii/S1470204517306071|journal=The Lancet Oncology|language=en|volume=18|issue=12|pages=e731–e741|doi=10.1016/s1470-2045(17)30607-1|pmid=29208439|year=2017}}
35. ^{{cite journal |vauthors=Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ |title=Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer |journal=Cancer Immunol Immunother |volume=63 |issue=7 |pages=721–35 |date=July 1, 2014 |doi= 10.1007/s00262-014-1549-4 |pmid=24711084 |pmc=4384696}}
36. ^{{cite journal |author1=Huang CT |author2=Workman CJ |author3=Flies D |author4=Pan X |author5=Marson AL |author6=Zhou G |author7=Hipkiss EL |author8=Ravi S |author9=Kowalski J |author10=Levitsky HI |author11=Powell JD |author12=Pardoll DM |author13=Drake CG |author14=Vignali DA. |title=Role of LAG-3 in regulatory T cells |journal=Immunity |volume=21 |issue=4 |pages=:503–13 |date=October 1, 2004 |doi= 10.1016/j.immuni.2004.08.010 |pmid=15485628}}
37. ^{{cite journal |vauthors=Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, Anders R, Netto G, Getnet D, Bruno TC, Goldberg MV, Pardoll DM, Drake CG |title=LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems |journal=J Clin Invest |volume=117 |issue=11 |pages=3383–92 |date=November 1, 2007 |doi= 10.1172/jci31184 |pmid=17932562 |pmc=2000807}}
38. ^{{ClinicalTrialsGov|NCT01968109|Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors}}
39. ^{{cite journal |vauthors=Martner A, Aydin E, Hellstrand K |title=NOX2 in autoimmunity, tumor growth and metastasis |journal=J Pathol |volume=247 |issue=2 |pages=151–154 |date=October 1, 2018 |doi= 10.1002/path.5175 |pmid=30270440}}
40. ^{{cite journal |vauthors=Philips GK, Atkins M |title=Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies |journal=Int Immunol |volume=27 |issue=1 |pages=39–46 |date=January 1, 2015 |doi= 10.1093/intimm/dxu095 |pmid=25323844}}
41. ^{{cite journal |vauthors=Hastings WD, Anderson DE, Kassam N, Koguchi K, Greenfield EA, Kent SC, Zheng XX, Strom TB, Hafler DA, Kuchroo VK |title=TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines |journal=Eur J Immunol |volume=39 |issue=9 |pages=2492–501 |date=September 1, 2009 |doi= 10.1002/eji.200939274 |pmid=19676072 |pmc=2759376}}
42. ^{{cite book |vauthors=Zhu C, Anderson AC, Kuchroo VK |title=TIM-3 and its regulatory role in immune responses |journal=Curr Top Microbiol Immunol |volume=350 |issue= |pages=1–15 |date=August 11, 2010 |doi= 10.1007/82_2010_84 |pmid=20700701|series=Current Topics in Microbiology and Immunology |isbn=978-3-642-19544-0 }}
43. ^{{cite journal |vauthors=Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, Lu LF, Gondek D, Wang Y, Fava RA, Fiser A, Almo S, Noelle RJ |title=VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses |journal=J Exp Med |volume=208 |issue=3 |pages=577–92 |date=March 14, 2011 |doi= 10.1084/jem.20100619 |pmid=21383057 |pmc=3058578}}
44. ^{{cite journal |vauthors=Lines JL, Pantazi E, Mak J, Sempere LF, Wang L, O'Connell S, Ceeraz S, Suriawinata AA, Yan S, Ernstoff MS, Noelle R |title=VISTA is an immune checkpoint molecule for human T cells |journal=Cancer Res |volume=74 |issue=7 |pages=1924–32 |date=April 1, 2014 |doi= 10.1158/0008-5472.CAN-13-1504 |pmid=24691993 |pmc=3979527}}
45. ^{{Cite journal |last=Läubli |first=Heinz |last2=Zippelius |first2=Alfred |last3=Varki |first3=Ajit |last4=Speiser |first4=Daniel E. |last5=Stenner |first5=Frank |last6=Egli |first6=Adrian |last7=Syedbasha |first7=Mohammedyaseen |last8=Amos |first8=Christopher I. |last9=Han |first9=Younghun |date=2018-11-01 |title=Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells |url=https://www.jci.org/articles/view/120612 |journal=The Journal of Clinical Investigation |language=en |volume=128 |issue=11 |pages=4912–4923 |doi=10.1172/JCI120612 |pmid=30130255 |pmc=6205408 |issn=0021-9738}}
46. ^{{Cite journal |last=Varki |first=Ajit |last2=Paulson |first2=James C. |last3=Crocker |first3=Paul R. |title=Siglecs and their roles in the immune system |url=https://www.nature.com/articles/nri2056 |journal=Nature Reviews Immunology |language=en |volume=7 |issue=4 |pages=255–266 |doi=10.1038/nri2056 |pmid=17380156 |issn=1474-1741 |via= |year=2007}}
47. ^{{Cite journal |last=Paulson |first=James C. |last2=Crocker |first2=Paul R. |last3=Macauley |first3=Matthew S. |title=Siglec-mediated regulation of immune cell function in disease |url=https://www.nature.com/articles/nri3737 |journal=Nature Reviews Immunology |language=en |volume=14 |issue=10 |pages=653–666 |doi=10.1038/nri3737 |pmid=25234143 |pmc=4191907 |issn=1474-1741 |year=2014}}
48. ^{{cite journal|last1=Pardoll|first1=Drew M.|title=The blockade of immune checkpoints in cancer immunotherapy|journal=Nature Reviews Cancer|date=22 March 2012|volume=12|issue=4|pages=252–264|doi=10.1038/nrc3239|pmid=22437870|pmc=4856023}}
49. ^{{Cite journal |url=https://www.economist.com/news/business/21721676-astrazenecas-imfinzi-costs-180000-years-treatment-cancer-drugs-are-getting-better-and |title=Cancer drugs are getting better and dearer |journal=The Economist |access-date=2017-05-19 |date=2017-05-04}}

1 : Immune system
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/11 22:17:18